LXR 0152

Drug Profile

LXR 0152

Alternative Names: Elirex

Latest Information Update: 03 May 2000

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator LXR Biotechnology
  • Class Anti-ischaemics; Lysophospholipids
  • Mechanism of Action Apoptosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Ischaemia; Ischaemic heart disorders; Liver disorders

Most Recent Events

  • 03 May 2000 Discontinued-Preclinical for Ischaemia in USA (IV)
  • 03 May 2000 Discontinued-Preclinical for Ischaemic heart disorders in USA (IV)
  • 03 May 2000 Discontinued-Preclinical for Liver disorders prevention in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top